The VOICE-COVID-19

NCT ID: NCT04508972

Last Updated: 2023-08-07

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

267 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-09-01

Study Completion Date

2023-03-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The VOICE-COVID study will evaluate the concordance of screening for symptoms of COVID-19 using a voice based device (Amazon Alexa) compared to manual screening by a study coordinator for individuals entering the Cardiology/Heart Failure clinic at the McGill University Health Centre.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study is an open-label, prospective, cross-over randomized study.

VOICE-COVID I: All individuals entering the Heart Failure (HF) Clinic of the McGill University Health Center will be asked to participate. A poster with instructions to ask the participants (employees or patients) to speak with the Amazon Alexa device. The participant will remain 6 feet away from the device. The Amazon Alexa will ask the survey questions. A study coordinator will then ask the same questions along with some additional questions about Amazon Alexa usability. VOICE-COVID II: A second cohort of 52 people will be then randomized to be screened for symptoms of COVID-19 with an Amazon Alexa or a coordinator. We will study the correlation between the Alexa response and the response to the study coordinator using K-squared statistic tests and screening question concordance.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Covid19

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Alexa Amazon

To test the use of the Amazon Alexa device as a tool to conduct screening of employees and patients at the point of entry into the Heart Failure (HF) Clinic of the McGill University Health Center.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adults \>=18 yrs who is entering the HF clinic
* Speaks either English or French

Exclusion Criteria

* None
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Amazon Web Services (AWS) Canada

UNKNOWN

Sponsor Role collaborator

McGill University Health Centre/Research Institute of the McGill University Health Centre

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Abhinav Sharma

Cardiologist

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Abhinav Sharma, MD

Role: PRINCIPAL_INVESTIGATOR

McGill University Health Centre/Research Institute of the McGill University Health Centre

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Muhc-Rimuhc

Montreal, Quebec, Canada

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Canada

References

Explore related publications, articles, or registry entries linked to this study.

Marques P, Emami A, Zhang G, Lopes RD, Razaghizad A, Avram R, Sharma A. Impact of age and comorbid heart failure on the utility of smart voice-assistant devices. Eur Heart J Digit Health. 2024 Feb 16;5(3):389-393. doi: 10.1093/ehjdh/ztae012. eCollection 2024 May.

Reference Type DERIVED
PMID: 38774370 (View on PubMed)

Sharma A, Marques P, Zhang G, Oulousian E, Chung SH, Ganni E, Lopes RD, Razaghizad A, Avram R. Voice-assisted Artificial Intelligence-enabled Screening for Severe Acute Respiratory Syndrome Coronavirus 2 Exposure in Cardiovascular Clinics: Primary Results of the VOICE-COVID-19-II Randomized Trial. J Card Fail. 2023 Oct;29(10):1456-1460. doi: 10.1016/j.cardfail.2023.05.004. Epub 2023 May 22.

Reference Type DERIVED
PMID: 37224994 (View on PubMed)

Oulousian E, Chung SH, Ganni E, Razaghizad A, Zhang G, Avram R, Sharma A. Voice-Based Screening for SARS-CoV-2 Exposure in Cardiovascular Clinics (VOICE-COVID-19-II): Protocol for a Randomized Controlled Trial. JMIR Res Protoc. 2023 Jan 31;12:e41209. doi: 10.2196/41209.

Reference Type DERIVED
PMID: 36719720 (View on PubMed)

Sharma A, Oulousian E, Ni J, Lopes R, Cheng MP, Label J, Henriques F, Lighter C, Giannetti N, Avram R. Voice-based screening for SARS-CoV-2 exposure in cardiovascular clinics. Eur Heart J Digit Health. 2021 Jun 16;2(3):521-527. doi: 10.1093/ehjdh/ztab055. eCollection 2021 Sep.

Reference Type DERIVED
PMID: 36713601 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2020-6583

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.